

Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are associated with proximal/middle segment of the LAD lesions in patients with stable coronary artery disease

Mehmet Balın · Ahmet Celik · M. Ali Kobat

Received: 6 September 2011 / Accepted: 15 November 2011 / Published online: 25 November 2011
© Springer-Verlag 2011

Abstract

Background/Objectives Atherosclerosis is the main underlying pathology of coronary artery disease (CAD), which is the leading cause of mortality worldwide. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is involved in multiple phases of vascular dysfunction, including endothelial dysfunction, atherosclerotic plaque formation, and destabilization. The purpose of the current study was to determine whether soluble LOX-1 is associated with proximal/mid and distal segment of the left anterior descending (LAD) artery lesion in patients with stable CAD.

Methods Sixty-four patients with proximal/mid segment of the LAD lesions and 51 patients with distal segments of the LAD lesions were included in this study. Soluble LOX-1 levels were measured in all study subjects.

Results Baseline characteristics of the two groups were similar. In stable CAD, patients with proximal/middle segment of the LAD lesions had significantly higher circulating soluble LOX-1 levels than patients with distal segments of the LAD lesions (1.07 ± 0.33 vs. 0.70 ± 0.17 ng/ml, $p < 0.001$). No correlation was found between plasma-soluble LOX-1 levels and fasting glucose, lipid profile. For predicting proximal/middle LAD lesions, the highest specificity (95,2%) and sensitivity (53,8%) levels were obtained at the cut-off value of 0.68.

Conclusion Our study demonstrated that serum-soluble LOX-1 levels were associated with proximal/mid segment of the LAD lesions. Furthermore, this study suggested soluble LOX-1 might be a useful biomarker of coronary plaque vulnerability in patients with stable CAD. Soluble

LOX-1, the novel biochemical marker, may provide new insights into not only risk stratification but also therapeutic strategy for CAD.

Keywords Atherosclerotic plaque · Coronary artery disease · Proximal/mid segment of the LAD lesions · Soluble lectin-like oxidized low-density lipoprotein receptor-1

Introduction

Cardiovascular disease (CVD) [1], including myocardial infarction (MI), unstable angina pectoris, sudden cardiac death and stroke, remains one of the leading causes of morbidity and mortality in the developed world. Atherosclerosis is the main cause of CVD, including ischemic stroke and coronary artery disease (CAD) [2–9]. Advances in recent research have provided greater understanding of the underlying pathophysiology of atherosclerosis and its clinical manifestations. Evidence now supports that atherosclerosis is a progressive, dynamic, and inflammatory process [6, 7, 10]. Atherosclerosis occurs preferentially at certain sites within the arterial tree—at the branching points of a coronary artery [5, 10]. Atherosclerotic lesions of the proximal segment of the left anterior descending (LAD) coronary artery constitute a special subgroup of CAD, given the high-risk profile [11, 12].

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), a type II membrane glycoprotein and scavenger receptor, is the major receptor for oxidized low-density lipoprotein (ox-LDL) in endothelial cells [13]. It is also expressed by macrophages and vascular smooth muscle cells [14]. LOX-1 has been implicated in vascular inflammation and atherosclerotic plaque formation and

M. Balın (✉) · A. Celik · M. A. Kobat
Department of Cardiology, Elazığ Education
and Research Hospital, Elazığ, Turkey
e-mail: mehmetbalina@yahoo.com

destabilization [15, 16]. LOX-1 is a receptor with an expression that is not constitutive but dynamically inducible [17]. In addition to ox-LDL, LOX-1 can also be activated by other risk factors of CAD, including shear stress, angiotensin II, proinflammatory cytokines, and C-reactive protein [18–21]. Activation of this receptor initiates intracellular signaling pathways leading to endothelial activation, dysfunction and apoptosis, and plaque destabilization [22]. LOX-1 is expressed on the cell surface and can be proteolytically cleaved at its membrane proximal extracellular domain and released as soluble forms (sLOX-1), which can be measured in the serum [23]. Since the level of soluble receptors in circulating blood may reflect the expression of membrane proteins and disease activities, sLOX-1 may be a potential biomarker of vascular disease.

In clinical and pathologic studies, the proximal and mid portions of the major coronary arteries have been identified as the most frequent sites of plaque rupture that have resulted in acute coronary events [24–30]. We therefore sought to clarify the link between circulating sLOX-1 levels and angiographic proximal/mid and distal LAD coronary lesions in stable CAD patients. The present study was the first to evaluate the relationship between sLOX-1 and proximal/mid and distal LAD coronary lesions.

Materials and methods

Patient population

From January 2010 to June 2011, we prospectively evaluated 1,984 patients, for elective coronary angiograms to determine the possible presence of CAD in our hospital, who had effort angina with suspected stable CAD. Stable CAD was defined as no recent deterioration or rest pain in the previous 6 months but angiographically documented coronary artery stenosis <50% and no previous MI. We enrolled totally 115 patients with non-significant coronary lesion, absence of >50% diameter stenosis in any coronary vessel ≥ 1.5 mm in diameter, into the study. Of these patients, 64 had proximal/mid segment of the LAD lesions (Group 1) and 51 had distal segments of the LAD lesions (Group 2). All participants provided written informed consent to participate in the study. The study protocol was approved by the local ethics committee, and the study was conducted in accordance with the Declaration of Helsinki and Good Clinical practice (GCP)/International Conference on Harmonization (ICH) guidelines.

Exclusion criteria included non-significant lesion in left circumflex and/or right coronary artery, >50% diameter stenosis in any coronary vessel, congestive heart failure (ejection fraction <50%), previous myocardial infarction, suspected myocarditis or pericarditis, diabetes mellitus,

stroke, known peripheral atherosclerotic disease, surgical coronary intervention, other major vascular surgical procedures, percutaneous coronary angioplasty, unstable angina pectoris, impaired renal function (creatinine ≥ 1.4 mg/dL), unstable endocrine or metabolic diseases, patients with concomitant inflammatory diseases such as infections and autoimmune disorders, acute/chronic hepatic or hepatobiliary disease and malignancy. Patients taking corticosteroids, anti-oxidant vitamins and alcohol were also excluded from the study.

Blood sampling and laboratory methods

Blood samples of all individuals were taken from an antecubital vein following an overnight fasting state just after angiography. After centrifugation at $3000\times g$ for 10 min, serum and plasma samples were frozen and stored at -80°C until an assay could be performed. Serum sLOX-1 levels were measured by a commercially available enzyme-linked immunosorbent assay kit (USCN Life Science, 430079, Wuhan, China). The detection limit for serum sLOX-1 level was 2.4 pg/mL with a coefficient of variation <5%. Analyses were performed by the immunologists, who were blinded to the condition of the samples. Triglyceride (TG), total cholesterol (Total-C), Low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) concentrations were measured by automated chemistry analyzer (Roche Diagnostics, Indianapolis, USA) using commercially available kits. We measured serum creatinine levels in all study patients and calculated the glomerular filtration rate (GFR) with MDRD formula.

Angiographic analysis

All patients underwent routine coronary angiography using the Judkins technique with digitized coronary angiography equipment (Siemens, Medical Solutions 2007, Munchen, Germany). All coronary angiograms were visually assessed by at least two experienced invasive cardiologists who were unaware of the patient's status, and a consensus was reached. For this study, we defined non-significant lesion as minimal lumen diameter stenosis <50% on the angiogram. Proximal/middle segment LAD lesions were defined as lesions from LAD ostium to beginning of second diagonal artery, and distal LAD lesions were defined as lesions from second diagonal artery to the end of the LAD.

Statistical analysis

Continuous variables were given as mean \pm SD; categorical variables were defined as percentages. Comparisons between Group-1 and Group-2 were carried out using an

independent samples *t* test. Sensitivity and specificity values of sLOX-1 levels for predicting proximal/mid LAD lesion were estimated using receiver operator characteristic (ROC) curve analysis. The cutoff level of sLOX-1 levels were determined using MedCalc 9.2.0.1 (MedCalc Software, Mariakerke, Belgium). Correlation analyses were performed using the Pearson coefficient of correlation. SPSS 15.0 software was used for basic statistical analysis (Version 15, SPSS Inc., and Chicago, IL, USA). A value of $p < 0.05$ was accepted as statistically significant.

Results

Table 1 shows the baseline characteristics of patients in two groups. There were no significant differences between two groups in age, gender, family history, history of hypertension, and smoke. The levels of fasting glucose, GFR (with MDRD formula), total-C, LDL-C, HDL-C, and triglyceride were not differing between groups (Table 1).

Significantly higher sLOX-1 levels in proximal/mid LAD lesion group (Group 1) than distal LAD lesion group (Group 2) were shown in Fig. 1 (sLOX-1 levels were 1.07 ± 0.33 in Group 1 and 0.70 ± 0.17 in Group 2; $p < 0.001$). There were no correlations between sLOX-1 levels and fasting glucose, GFR, LDL-C, HDL-C, total-C,




Fig. 1 The comparison of sLOX-1 levels between two groups (Group 1 proximal/middle LAD lesion Group, Group 2 distal LAD lesion Group, sLOX-1 lectin-like oxidized low-density lipoprotein receptor-1) sLOX-1 levels were 1.07 ± 0.33 in Group 1 and 0.70 ± 0.17 in Group 2. $P < 0.05$ was accepted statistically significant




Fig. 2 ROC curve of sLOX-1 levels in study patients for localization of lesion in left anterior descending artery. AUC area under curve, SE standard error, CI confidence interval

Table 1 The demographic and clinical characteristics of patients in two groups

	Group 1 (n=64) ^a	Group 2 (n=51) ^b	P value
Age (years)	58 ± 7	60 ± 9	0.1
Female (%)	40	39	0.8
Fasting glucose (mg/dL)	94 ± 9	96 ± 10	0.2
Serum creatinine (mg/dL)	0.84 ± 0.19	0.87 ± 0.16	0.3
GFR (%)	90.3 ± 8.8	90.1 ± 9.7	0.9
Lipid profile (mg/dL)			
Total-C	207 ± 25	213 ± 29	0.3
LDL-C	127 ± 19	123 ± 20	0.3
HDL-C	44 ± 10	46 ± 13	0.4
Triglyceride	196 ± 69	195 ± 76	0.9
History of (%)			
Family	59	41	0.2
HT	50	54	0.3
Smoke	48	45	0.4

Data expressed as mean ± SD or percentage

Total-C total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, DM diabetes mellitus, HT hypertension, GFR glomerular filtration rate with MDRD formula

* $P < 0.05$ was accepted statistically significant

^a Group 1 proximal/middle LAD lesion Group

^b Group 2 distal LAD lesion Group

and triglyceride levels, separately. In Fig. 2, an ROC curve is used to identify the ability of sLOX-1 levels to predict the proximal/mid LAD lesion. The area under the ROC curve was 0.837 for the sLOX-1 levels ($P = 0.0001$). The sensitivity and specificity values of the sLOX-1 levels were 53.8% and 95.2%, respectively (cut off value was 0.68).

Discussion

The results of this study showed that among patients with stable CAD, those with proximal/mid segment of the LAD lesions had significantly higher circulating sLOX-1 levels than those with distal segment of the LAD lesions. To the best of our knowledge, this is the first study to show that the serum levels of sLOX-1 represent a marker of atherosclerotic plaque localization in stable CAD patients. Serum sLOX-1 levels were associated plaque localization lesions that might predict vulnerable plaques. This study suggested

sLOX-1 might be a useful biomarker of coronary plaque vulnerability in patients with stable CAD.

Atherosclerosis is a chronic, progressive, dynamic, and inflammatory disease with a long asymptomatic phase. Disease progression can lead eventually to the occurrence of acute cardiovascular events such as MI, unstable angina pectoris, and sudden cardiac death. While the disease is still in a sub-clinical stage, however, several invasive and noninvasive imaging techniques, including coronary angiography, intravascular ultrasonography, B-mode ultrasonography, computed tomography, magnetic resonance imaging, and assessment of inflammatory biomarkers, have been used to detect and/or diagnose the presence of atherosclerotic lesions and its functional status, facilitate risk stratification, and measure atherosclerosis progression and regression.

Advances in recent research have provided greater understanding of the underlying pathophysiology of atherosclerosis and its clinical manifestations. Atherosclerotic plaques consist of lipids, inflammatory cells, connective-tissue elements, smooth-muscle cells, thrombi, and calcium deposits [5, 7, 10, 31]. All aspects of plaque formation and the progressive atherosclerotic process are related to inflammatory responses and atherosclerosis occurs preferentially at certain sites within the arterial tree, at the branching points of a coronary artery [5, 10]. In clinical and pathologic studies, the proximal and mid portions of the major coronary arteries have been identified as the most frequent sites of plaque rupture that have result in ACS [24–30]. In addition, Katritsis et al. [32] reported that the majority of culprit lesions on the LAD that result in ACS are located within the first 4 cm from its origin and before the second septal or the second diagonal side branch.

Atherosclerotic lesions of the proximal segment of the LAD constitute a special subgroup of CAD, given the high-risk profile [11, 12]. Patients with proximal LAD occlusion in association with low left ventricular ejection fraction have been reported to have 19-fold higher mortality than the general population [33]. Katritsis et al. [32] postulated that rupture of vulnerable plaques and subsequent development of thrombotic lesions along the coronary tree may depend on several anatomic parameters, such as proximity of side branches and bifurcations, angulation of the relevant coronary segment, and axial bending during the cardiac cycle. All these anatomic features have been correlated with hemodynamic parameters that may potentially affect plaque rupture and subsequent thrombosis [34, 35].

LDL-C is recognized as one of the primary factors in the development and progression of atherosclerosis [36, 37]. LDL-C undergoes oxidative modification in arterial walls in situ and becomes ox-LDL with atherogenic properties [38]. Proinflammatory stimuli promote LDL-C oxidative

modification, and ox-LDL provokes inflammation; thus oxidative stress and inflammation in arterial walls are closely linked. Oxidative stress and subsequent inflammation have been characterized in atherosclerosis, from its beginning, such as the state of endothelial dysfunction, to its end-sequelae, such as acute MI and stroke [39]. Ox-LDL changes the secretory activities of endothelium and causes it to become dysfunctional [40]. The affected endothelium expresses a lot of surface molecules that attract circulating inflammatory cells and facilitate their migration into the subendothelial space [10]. Ox-LDL inhibits the expression of constitutive nitric oxide synthase [41], induces expression of adhesion molecules, and facilitates inflammatory cells to adhere to the intima [42]. Some of ox-LDL can be detected in circulating blood and have been shown to be elevated in ACS [43, 44].

Interactions between ox-LDL and its receptor LOX-1, a type II membrane glycoprotein, is the major receptor for ox-LDL in endothelial cells [13], appear to play key roles in ox-LDL-induced vascular dysfunction, including apoptosis of endothelial cells, and monocytes/macrophages, expression of adhesion molecules and activates the inflammatory cascade activation, which evokes atherosclerotic plaque rupture or erosion [45–48]. Expression of LOX-1 is upregulated by angiotensin II, free radicals, inflammatory cytokines, and shear stress [49–51]. Furthermore, LOX-1 activates MMPs [48] resulting in collagen degradation and initiation of plaque rupture—the most proximate cause of ACS. Many studies [52, 53] have shown that an increase in the activity and expression of MMPs plays a central role in the composition of atherosclerotic plaques. Ox-LDL, LOX-1, and MMPs have been found to be co-localized in advanced atherosclerotic plaques [43, 54]. Their interaction may lead to the instability of atherosclerotic plaques. These pathological effects of LOX-1 not only initiate atherosclerotic lesion formation, but also contribute to the vulnerability of a plaque to rupture. Circulating levels of sLOX-1 are increased in patients with unstable coronary syndromes [55]. In addition, a recent pilot study has shown that sLOX-1 predicted prognosis, such as future recurrence of ACS or death, in patients with ACS [56]. In experimental animal models, LOX-1 expression is closely associated with morphological plaque instability and cell apoptosis, as well as with the expression of MMPs and tissue factor, all of which are associated with plaque rupture and thrombus formation [57–59]. A study [60] demonstrated that LOX-1 deficiency significantly decreases the formation of atherosclerotic lesions.

Inflammatory process begins from the earliest phase of atherosclerosis, formation of fatty streak, involving the leukocyte infiltration and link between plaque formation and acute plaque rupture, leading to ACS [45]. Although

a coronary artery plaque large enough to cause significant stenosis can lead to myocardial ischemia, critical stenosis does not always occur [10, 31, 61]. Current thinking is that plaque activation rather than stenosis leads to thrombus formation and myocardial ischemia or infarction [7]. The expanding plaque may eventually become exposed due to endothelial erosion or plaque rupture, each leading to thrombosis [10, 31]. Both plaque rupture and endothelial erosion are related to increased inflammatory activity within the plaque, and the main stimulus for this inflammation is the reaction of oxidized intimal LDL and macrophages [31]. Minor episodes of endothelial erosion or plaque rupture may occur asymptotically; however, repeated cycles of erosion or rupture, thrombosis, and repair gradually increase the size of the plaque [10].

Atherosclerosis occurs frequently at the branching points of a coronary artery [62]. A higher incidence of ruptured plaques was detected before and after bifurcation in the proximal LAD and at sites of vessel angulation in the LAD [32]. El Fawal et al. [24], in a pathologic study on 59 patients who died of MI in Glasgow, provided evidence that thrombosis are distributed in the proximal coronary vessels. In addition, in young subjects less than 40 years of age, dying of non-cardiovascular causes, vulnerable coronary plaques are concentrated proximally, and diminish with distance in all coronary arteries [25]. These observations suggest that proximal coronary plaques are more prone to rupture. Wang and colleagues [29] demonstrated that acute coronary occlusions leading to MI tend to cluster in predictable “hot spots” within the proximal third of the coronary arteries, particularly the LAD and left circumflex. A pathologic study has also demonstrated that over 50% of thin-cap fibroatherosclerotic plaques occur in the proximal portions of the major coronary arteries, another one-third in the mid portion of these arteries, and the rest distributed in distal segments [30]. Valgimigli et al. [63, 64], in intravascular ultrasound studies, have shown that plaque distance from the coronary ostium is an independent determinant of relative lipid content. Plaques located within the proximal 20 mm of coronary vessels are relatively richer in lipid content compared with those more distally located [63].

In conclusion, the present study firstly showed that sLOX-1, a biomarker for plaque formation, progression and/or destabilization; levels were associated with proximal/mid segment of the LAD lesions that might predict vulnerable plaques. These results suggested that the sLOX-1 might be a useful biomarker of plaque vulnerability in patients with stable CAD. Soluble LOX-1 can be used as a target for imaging of atherosclerotic plaque. Soluble LOX-1, the novel biochemical marker, may provide new insights into not only risk stratification but also therapeutic strategy

for CAD. However, the limitation of the present study would be the relatively small sample size, and thus the present findings should be confirmed by multicenter studies with larger sample sizes.

Acknowledgments No funding supported this study.

References

1. Mensah GA, Brown DW (2007) An overview of cardiovascular disease burden in the United States. *Health Aff (Millwood)* 26:38–48
2. Grobbee DE, O’Leary DH, Bots ML, Measuring Effects on intima media Thickness: an Evaluation of Rosuvastatin study group et al (2004) Measuring Effects on intima media Thickness: an Evaluation of Rosuvastatin in sub clinical atherosclerosis—the rationale and methodology of the METEOR study. *Cardiovasc Ther* 18:231–238
3. Viles-Gonzalez JF, Fuster V, Badimon JJ (2004) Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. *Eur Heart J* 25:1197–1207
4. Jensen LO, Thyssen P, Pedersen KE, Stender S, Haghfelt T (2004) Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. *Circulation* 110:265–270
5. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH (2001) Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. *Ann Intern Med* 134: 224–238
6. Ohashi R, Mu H, Yao Q, Chen C (2004) Atherosclerosis: immunopathogenesis and immunotherapy. *Med Sci Monit* 10:RA255–RA260
7. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 352:1685–1695
8. Ben-Haim S, Israel O (2006) PET/CT for atherosclerotic plaque imaging. *Q J Nucl Med Mol Imaging* 50:53–60
9. Van Mieghem CA, McFadden EP, de Feyter PJ et al (2006) Noninvasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities: the Integrated Biomarker and Imaging Study (IBIS). *J Am Coll Cardiol* 47:1134–1142
10. Weissberg PL (2000) Atherogenesis: current understanding of the causes of atheroma. *Heart* 83:247–252
11. Valencia J, Bordes P, Berenguer A, Mainar V, Ruiz Nodar JM, Arrarte V (2002) Long-term follow-up of patients with proximal left anterior descending coronary artery stenosis treated with stent. *Rev Esp Cardiol* 55:607–615
12. Brambilla N, Repetto A, Bramucci E et al (2005) Directional coronary atherectomy plus stent implantation vs. left internal mammary artery bypass grafting for isolated proximal stenosis of the left anterior descending coronary artery. *Catheter Cardiovasc Interv* 64:45–52
13. Sawamura T, Kume N, Aoyama T et al (1997) An endothelial receptor for oxidized low-density lipoprotein. *Nature* 386:73–77
14. Yoshida H, Kondratenko N, Green S, Steinberg D, Quehenberger O (1998) Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. *Biochem J* 334:9–13
15. Vohra RS, Murphy JE, Walker JH, Ponnambalam S, Homer-Vanniasinkam S (2006) Atherosclerosis and the Lectin-like OXidized low-density lipoprotein scavenger receptor. *Trends Cardiovasc Med* 16:60–64

16. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G (2006) Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. *Cardiovasc Res* 69:36–45
17. Kume N, Murase T, Moriwaki H et al (1998) Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. *Circ Res* 83:322–327
18. Conti CR, Mehta JL (1987) Acute myocardial ischemia: role of atherosclerosis, thrombosis, platelet activation, coronary vasospasm, and altered arachidonic acid metabolism. *Circulation* 75:V84–V95
19. Lee RT, Libby P (1997) The unstable atheroma. *Arterioscler Thromb Vasc Biol* 17:1859–1867
20. Rouis M, Adamy C, Duverger N et al (1999) Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. *Circulation* 100:533–540
21. Pasterkamp G, Schoneveld AH, Hijnen DJ et al (2000) Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteinases 1, 2 and 9 in the human coronary artery. *Atherosclerosis* 150:245–253
22. Li D, Mehta JL (2000) Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. *Arterioscler Thromb Vasc Biol* 20:1116–1122
23. Murase T, Kume N, Kataoka H et al (2000) Identification of soluble forms of lectin-like oxidized LDL receptor-1. *Arterioscler Thromb Vasc Biol* 20:715–720
24. El Fawal MA, Berg GA, Wheatley DJ, Harland WA (1987) Sudden coronary death in Glasgow: nature and frequency of acute coronary lesions. *Br Heart J* 57:329–335
25. Fox B, James K, Morgan B, Seed A (1982) Distribution of fatty and fibrous plaques in young human coronary arteries. *Atherosclerosis* 41:337–347
26. Gibson CM, Kirtane AJ, Murphy SA et al (2003) Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. *J Thromb Thrombolysis* 15:189–196
27. Hochman JS, Phillips WJ, Ruggieri D, Ryan SF (1988) The distribution of atherosclerotic lesions in the coronary arterial tree: relation to cardiac risk factors. *Am Heart J* 116:1217–1222
28. Vieweg WV, Alpert JS, Johnson AD et al (1979) Distribution and severity of coronary artery disease in 500 patients with angina pectoris. *Cathet Cardiovasc Diagn* 5:319–330
29. Wang JC, Normand SL, Mauri L, Kuntz RE (2004) Coronary artery spatial distribution of acute myocardial infarction occlusions. *Circulation* 110:278–842
30. Virmani R, Burke AP, Farb A, Kolodgie FD (2006) Pathology of the vulnerable plaque. *J Am Coll Cardiol* 47(8 Suppl):C13–C18
31. Davies MJ (2000) The pathophysiology of acute coronary syndromes. *Heart* 83:361–366
32. Katritsis DG, Efsthathopoulos EP, Pantos J, Korovesis et al (2008) Anatomic characteristics of culprit sites in acute coronary syndromes. *J Interv Cardiol* 21:140–150
33. Valencia J, Berenguer A, Mainar V et al (2006) Two-year follow-up of sirolimus-eluting stents for the treatment of proximal left anterior descending coronary artery stenosis. *J Interv Cardiol* 19:126–134
34. Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. *Circulation* 92:657–671
35. Katritsis DG, Pantos J, Efsthathopoulos E (2007) Hemodynamic factors and atheromatic plaque rupture in the coronary arteries: from vulnerable plaque to vulnerable coronary segment. *Coron Artery Dis* 18:229–237
36. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). *JAMA* 285:2486–2497
37. Smith SC Jr, Allen J, Blair SN et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. *J Am Coll Cardiol* 47:2130–2139
38. Witztum JL, Steinberg D (1991) Role of oxidized low density lipoprotein in atherogenesis. *J Clin Invest* 88:1785–1792
39. Chen J, Mehta JL (2004) Role of oxidative stress in coronary heart disease. *Indian Heart J* 56:163–173
40. Erl W, Weber PC, Weber C (1998) Monocytic cell adhesion to endothelial cells stimulated by oxidized low density lipoprotein is mediated by distinct endothelial ligands. *Atherosclerosis* 136:297–303
41. Keaney JF Jr, Guo Y, Cunningham D, Shwaery GT, Xu A, Vita JA (1996) Vascular incorporation of alpha-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. *J Clin Invest* 98:386–394
42. Mehta A, Yang B, Khan S, Hendricks JB, Stephen C, Mehta JL (1995) Oxidized low-density lipoproteins facilitate leukocyte adhesion to aortic intima without affecting endothelium-dependent relaxation. Role of P-selectin. *Arterioscler Thromb Vasc Biol* 15:2076–2083
43. Ehara S, Ueda M, Naruko T et al (2001) Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. *Circulation* 103:1955–1960
44. Tsimikas S, Witztum JL (2001) Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. *Circulation* 103:1930–1932
45. Kume N, Kita T (2002) New scavenger receptors and their functions in atherogenesis. *Curr Atheroscler Rep* 4:253–257
46. Kataoka H, Kume N, Miyamoto S, Minami M, Morimoto M, Hayashida K et al (2001) Oxidized LDL modulates Bax/Bcl-2 through the lectinlike Ox-LDL receptor-1 in vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 21:955–960
47. Kume N, Kita T (2004) Apoptosis of vascular cells by oxidized LDL: involvement of caspases and LOX-1 and its implication in atherosclerotic plaque rupture. *Circ Res* 94:269–270
48. Li D, Liu L, Chen H, Sawamura T, Ranganathan S, Mehta JL (2003) LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. *Circulation* 107:612–617
49. Li DY, Zhang YC, Phillips MI, Sawamura T, Mehta JL (1999) Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation. *Circ Res* 84:1043–1049
50. Kume N, Murase T, Moriwaki H et al (1998) Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. *Circ Res* 83:322–327
51. Murase T, Kume N, Korenaga R et al (1998) Fluid shear stress transcriptionally induces lectin-like oxidized LDL receptor-1 in vascular endothelial cells. *Circ Res* 83(3):328–333
52. Silence J, Lupu F, Collen D, Lijnen HR (2001) Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. *Arterioscler Thromb Vasc Biol* 21:1440–1445
53. Lemaître V, O'Byrne TK, Borczuk AC, Okada Y, Tall AR, D'Armiento J (2001) ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. *J Clin Invest* 107:1227–1234

54. Chen H, Li D, Sawamura T, Inoue K, Mehta JL (2000) Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. *Biochem Biophys Res Commun* 276:1100–1104
55. Hayashida K, Kume N, Murase T et al (2005) Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. *Circulation* 112:812–818
56. Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kita T (2010) Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts prognosis after acute coronary syndrome—a pilot study. *Circ J* 74:1399–1404
57. Ishino S, Mukai T, Kume N et al (2007) Lectin-like oxidized LDL receptor-1 (LOX-1) expression is associated with atherosclerotic plaque instability—analysis in hypercholesterolemic rabbits. *Atherosclerosis* 195:48–56
58. Kuge Y, Kume N, Ishino S et al (2008) Prominent lectin-like oxidized low density lipoprotein (LDL) receptor-1 (LOX-1) expression in atherosclerotic lesions is associated with tissue factor expression and apoptosis in hypercholesterolemic rabbits. *Biol Pharm Bull* 31:1475–1482
59. Ishino S, Mukai T, Kuge Y et al (2008) Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with ^{99m}Tc-labeled anti-LOX-1 antibody: potential agent for imaging of vulnerable plaque. *J Nucl Med* 49:1677–1685
60. Mehta JL, Sanada N, Hu CP et al (2007) Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. *Circ Res* 100:1634–1642
61. Sipahi I, Tuzcu EM, Schoenhagen P et al (2006) Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial. *Atherosclerosis* 189:229–235
62. Stary HC (1989) Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. *Arteriosclerosis* 9(1 Suppl):I19–I32
63. Valgimigli M, Rodriguez-Granillo GA, Garcia-Garcia HM et al (2006) Distance from the ostium as an independent determinant of coronary plaque composition in vivo: an intravascular ultrasound study based radiofrequency data analysis in humans. *Eur Heart J* 27:655–663
64. Valgimigli M, Rodriguez-Granillo GA, Garcia-Garcia HM et al (2007) Plaque composition in the left main stem mimics the distal but not the proximal tract of the left coronary artery: influence of clinical presentation, length of the left main trunk, lipid profile, and systemic levels of C-reactive protein. *J Am Coll Cardiol* 49:23–31